Skip to main content
Local News

ISB Leading NCI Comprehensive Cancer Center to Study Sequential Targeted Inhibitors and Immunotherapies

By September 29, 2022No Comments

The National Cancer Institute awarded the Institute for Systems Biology (ISB) a 5-year, $13 million grant to lead a collaborative cancer center and study sequential combinations of targeted inhibitors and immunotherapies.

The program – called Spatiotemporal Tumor Analytics for Guiding Sequential Targeted Inhibitor-Immunotherapy Combinations, or ST-Analytics – is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.